Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nadica Matevska-Geskovska"'
Autor:
Aleksandar Dimkovski, Evgenija Mihajloska, Krume Jakovski, Zoran Sterjev, Nadica Matevska Geskovska, Zorica Naumovska, Aleksandra Kapedanovska Nestorovska, Ljubica Suturkova, Aleksandar Dimovski
Publikováno v:
Macedonian Pharmaceutical Bulletin. 68:393-394
Autor:
Rodney A. Rosalia, Petar Ugurov, Aleksandra Kapedanovska-Nestorovska, Nadica Matevska Geskovska, Zan Mitrev, Zoran Sterjev, Aleksandar Dimovski, Ljubica Suturkova
Publikováno v:
Pharmacogenomics and Personalized Medicine. 12:287-295
Aims The present observational cohort study evaluated the association between the AKR1D1*36 (rs1872930) allele and the risk of major adverse cardiovascular and cerebrovascular events (MACCE) in clopidogrel treated patients. Methods We screened 198 co
Autor:
Aleksandra Kapedanovska Nestorovska, Zorica Naumovska, Zoran Sterjev, Nadica Matevska Geskovska, Aleksandar Dimovski, Krume Jakovski, Ljubica Suturkova
Publikováno v:
Macedonian Pharmaceutical Bulletin. 64:57-62
AKR1D1 has been recently recognized as novel candidate gene regulating CYP450 coexpression. The AKR1D1 3’-UTR SNP (rs1872930) functional genetic variation was considered as important source of phenotypic variation in the activity of CYP450. The min
Autor:
Nikola Geskovski, Boguslaw Szczupak, Rozafa Koliqi, Jordi Llop, Aleksandar Dimovski, Sonja Ugarkovic, Katerina Goracinova, Delyan R. Hristov, Gjorgji Petruševski, Eneko San Sebastián, Nadica Matevska-Geskovska, Vanessa Gómez Vallejo, Marco P. Monopoli, Simona Dimchevska
Publikováno v:
International Journal of Pharmaceutics. 533:389-401
The aim of our study was to develop and compare the biological performance of two types of biodegradable SN-38 loaded nanoparticles (NPs) with various surface properties, composed of low and high Mw triblock PLGA-PEG-PLGA copolymers, applying rationa
Autor:
Nadica Matevska Geskovska, Krume Jakjovski, Ljubica Suturkova, Zorica Naumovska, Aleksandar Dimovski, Kristina Mladenovska, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev
Publikováno v:
Acta Pharmaceutica
Volume 69
Issue 3
Acta Pharmaceutica, Vol 69, Iss 3, Pp 399-412 (2019)
Volume 69
Issue 3
Acta Pharmaceutica, Vol 69, Iss 3, Pp 399-412 (2019)
The relative contribution of CYP2C9 allelic variants to the pharmacokinetics (PK) of ibuprofen (IBP) enantiomers has been studied extensively, but the potential clinical benefit of pharmacogenetically guided IBP treatment is not evident yet. The role